Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ChiCTR2600126531) titled 'A single-arm, stratified enrollment clinical study of Romiplostim N01 combined with Azacitidine in the treatment of low- and intermediate-risk myelodysplastic syndromes' on June 10.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Fujian Provincial Hospital Affiliated to Fuzhou University
Condition:
low and intermediate risk myelodysplastic syndromes
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-06-15
Target Sample Size: Experimental group:53;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=32752...